WellSIM Biomedical Technologies is a life science technology company backed by Illumina Accelerator, dedicated to cutting-edge extracellular vesicle isolation and analysis technology for research and clinical applications.

Extracellular vesicles are small lipid bilayer particles, which encapsulate biomolecules including lipids, proteins, and nucleic acids. They are secreted by most cell types and present in nearly all body fluids. EVs play a pivotal role in cellular communication and signaling with many important physiological and pathological implications. The EVs circulating in the blood and other body fluids of patients contain specific signatures or biomarkers that can reflect the disease state. Thus, profiling of EV-derived biomarkers (e.g., DNA, RNA, protein, and lipid) provides a promising approach for early diagnoses and prognosis of various diseases, such as cancers, neurodegenerative diseases, and autoimmune diseases. Moreover, EVs are emerging as a novel therapeutic platform that can deliver therapeutic materials to the target tissues and cells.

WellSIM is currently offering early access custom service for single-EV protein marker analysis based on our EXODOTS technology. We expected to launch the first commercial kit in 2023.